ReWalk Robotics Ltd. (NASDAQ:RWLK)’s share price dropped 7.5% during mid-day trading on Monday . The company traded as low as $6.62 and last traded at $6.80, with a volume of 58,983 shares traded. The stock had previously closed at $7.35.

RWLK has been the topic of a number of recent research reports. Zacks Investment Research upgraded ReWalk Robotics from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Tuesday, May 10th. Jefferies Group restated a “buy” rating and issued a $16.00 target price on shares of ReWalk Robotics in a report on Sunday, May 8th.

The firm’s market cap is $87.22 million. The firm’s 50-day moving average price is $7.06 and its 200 day moving average price is $9.27.

ReWalk Robotics (NASDAQ:RWLK) last announced its earnings results on Thursday, May 5th. The medical device company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.12. The business earned $2.06 million during the quarter, compared to analyst estimates of $1.56 million. During the same period in the previous year, the firm earned ($0.48) earnings per share. The firm’s revenue was up 224.6% compared to the same quarter last year. Analysts expect that ReWalk Robotics Ltd. will post ($2.11) EPS for the current fiscal year.

In other news, Director Wayne Weisman sold 16,148 shares of the stock in a transaction on Friday, May 20th. The stock was sold at an average price of $9.09, for a total value of $146,785.32. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Scp Vitalife Partners (Israel) sold 4,043 shares of the stock in a transaction on Friday, May 20th. The shares were sold at an average price of $9.09, for a total value of $36,750.87. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in ReWalk Robotics stock. EAM Investors LLC purchased a new position in shares of ReWalk Robotics Ltd. (NASDAQ:RWLK) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 93,333 shares of the medical device company’s stock, valued at approximately $1,351,000. EAM Investors LLC owned approximately 0.77% of ReWalk Robotics at the end of the most recent reporting period.

ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow wheelchair-bound individuals with mobility impairments or other medical conditions the ability to stand and walk. The Company offers ReWalk, an exoskeleton that uses its tilt-sensor technology, and an on-board computer and motion sensors to drive motorized legs that power movement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.